eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Actavis UK Ltd

Whiddon Valley, Barnstaple, Devon, EX32 8NS, UK
Telephone: +44 (0)1271 311 200
Fax: +44 (0)1271 346 106
WWW: http://www.actavis.co.uk
Medical Information Direct Line: +44 (0)1271 311 257
Medical Information e-mail: medinfo@actavis.co.uk

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 31/10/2011
SPC Dermidex Dermatological Cream


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Dermidex Dermatological Cream.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Dermidex Dermatological Cream contains:

Lidocaine 1.20% w/w

Alcloxa 0.25% w/w

Chorobutanol 1.00% w/w

Cetrimide 0.50% w/w

For excipients, see 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Cream. A smooth white cream, free from lumps, non greasy with an even distribution of emulsion droplets.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Antiseptic, anaesthetic, anti-irritant, and emollient agent. For the treatment of mild pain caused by minor skin cuts, scratches and grazes (chapping) and soreness caused by detergents, soaps, deodorants and jewellery and bites and stings.


Go to top of the page
4.2 Posology and method of administration

Adults, Children (age 4 and above) and the Elderly:

Apply to the affected area every 3 hours

Not suitable for children aged less than 4 years.

Route of administration: Cream for cutaneous use.


Go to top of the page
4.3 Contraindications

Dermidex Cream is contraindicated where there is hypersensitivity to cetrimide, chlorobutanol, lidocaine or other local anaesthetics of the amide type, or any of the other ingredients.


Go to top of the page
4.4 Special warnings and precautions for use

For external use only. Keep out of reach and sight of children.

The product should not be used for longer than 7 days without seeking medical advice.

Avoid contact with the eyes.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

Lidocaine crosses the placenta and is distributed into breast milk. As with all medicines use with care.


Go to top of the page
4.7 Effects on ability to drive and use machines

No or negligible influence.


Go to top of the page
4.8 Undesirable effects

Occasionally there have been reports of skin reaction with all such preparations.


Go to top of the page
4.9 Overdose

Overdose is unlikely.

Accidental ingestion may result in anaesthesia of the upper respiratory tract, nausea, vomiting and abdominal discomfort. Ingestion of very large quantities could result in CNS and cardiovascular toxicity. Treatment should be symptomatic and supportive.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Other dermatologicals D11A

Not applicable.


Go to top of the page
5.2 Pharmacokinetic properties

Not applicable


Go to top of the page
5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Cetyl Alcohol

Glyceryl Monostearate

Isopropyl Myristate

Light Liquid Paraffin

Purified Water

Phenoxyethanol

Sorbitol Solution

Stearyl Alcohol 1895

Perfume Sport 14412C


Go to top of the page
6.2 Incompatibilities

None known


Go to top of the page
6.3 Shelf life

36 months unopened


Go to top of the page
6.4 Special precautions for storage

None


Go to top of the page
6.5 Nature and contents of container

Lacquered covex tube with a low or medium density Polyethylene cap in a carton. Aluminium tubes with a Polyamide internal lacquer, a membrane nozzle fitted with a full skirted, spiked white Polyethylene cap in a carton.

Pack sizes: 3g, 4g, 5g, 7.5g, 10g, 30g & 50g.


Go to top of the page
6.6 Special precautions for disposal and other handling

For external use only.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Actavis Group PTC ehf

Reykjavikurvegi 76-78

220 Hafnarfjordur

Iceland.


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 30306/0068


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

2 December 2002


Go to top of the page
10. DATE OF REVISION OF THE TEXT

17/10/11


Go to top of the page
11 DOSIMETRY (IF APPLICABLE)

Not Applicable


Go to top of the page
12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS (IF APPLICABLE)

Not Applicable



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/21163/SPC/


Active Ingredients/Generics

 
   cetrimide
   chlorobutanol
   lidocaine
   alcloxa